STAT+: Insulin makers, PBMs echo old finger-pointing in Senate hearing
A Senate hearing on high insulin costs billed as a blockbuster showdown with drugmakers and middlemen turned out to be a familiar case of political theater that appeared to satisfy…
A Senate hearing on high insulin costs billed as a blockbuster showdown with drugmakers and middlemen turned out to be a familiar case of political theater that appeared to satisfy no one.
The nation’s three biggest insulin makers, Eli Lilly, Novo Nordisk, and Sanofi, and the trio of middlemen known as pharmacy benefit managers, Express Scripts, OptumRx and CVS Health, testified Wednesday in a three-hour hearing before the Senate Health, Education, Labor, and Pensions Committee. The hearing sets up a debate by the same committee Thursday over a package of bills aimed at PBM reform.
What's Your Reaction?
